Verified factor-similar pair

FNDA vs QVMS

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
87
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • QVMS has the higher backtested relative Sharpe (1.218 vs 1.059).
  • QVMS has the lower published fee (0.15% vs 0.25%).
  • QVMS is cheaper on dividend valuation (131 vs 148, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

FNDA

Schwab Fundamental U.S. Small Company ETF
SMB
Adj. R2
0.977
Rel. Sharpe
1.059
Mkt beta
1.02
AUM
US$9.8B
MER
0.25%
Valuation
148

QVMS

Invesco S&P SmallCap 600 QVM Multi-factor ETF
SMB
Adj. R2
0.974
Rel. Sharpe
1.218
Mkt beta
0.98
AUM
US$217M
MER
0.15%
Valuation
131

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
FNDA
+0.74
|t|
+24.7
QVMS
+1.00
|t|
+20.2
diff -0.26
HML
FNDA
+0.26
|t|
+9.0
QVMS
+0.23
|t|
+4.4
diff +0.02
RMW
FNDA
+0.15
|t|
+4.3
QVMS
+0.19
|t|
+4.2
diff -0.04
CMA
FNDA
+0.04
|t|
+1.1
QVMS
+0.01
|t|
+0.1
diff +0.04
UMD
FNDA
+0.00
|t|
+0.1
QVMS
+0.07
|t|
+2.1
diff -0.07

Why This Pair Matches

Exposure level
84
Exposure shape
100
Mkt beta diff
0.03
Rel. Sharpe diff
0.159

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

FNDA fund page QVMS fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.